The risk of Alzheimer's disease (AD) is higher in patients with type 2 diabetes mellitus (T2DM). Previous studies in high-fat diet-induced AD animal models have shown that brain insulin resistance in these animals leads to the accumulation of amyloid beta (Ab) and the reduction in GSK-3b phosphorylation, which promotes tau phosphorylation to cause AD. No therapeutic treatments that target AD in T2DM patients have yet been discovered. Agmatine, a primary amine derived from L-arginine, has exhibited anti-diabetic effects in diabetic animals. The aim of this study was to investigate the ability of agmatine to treat AD induced by brain insulin resistance. ICR mice were fed a 60% high-fat diet for 12 weeks and received one injection of streptozotocin (100 mg/kg/ip) 4 weeks into the diet. After the 12-week diet, the mice were treated with agmatine (100 mg/kg/ip) for 2 weeks. Behaviour tests were conducted prior to sacrifice. Brain expression levels of the insulin signal molecules p-IRS-1, p-Akt, and p-GSK-3b and the accumulation of Ab and p-tau were evaluated. Agmatine administration rescued the reduction in insulin signalling, which in turn reduced the accumulation of Ab and p-tau in the brain. Furthermore, agmatine treatment also reduced cognitive decline. Agmatine attenuated the occurrence of AD in T2DM mice via the activation of the blunted insulin signal.
Introduction
Clinical and epidemiological studies indicate a higher risk of Alzheimer's disease (AD) among patients with type 2 diabetes mellitus (T2DM) (Craft and Watson, 2004) . Previous studies have found a high-fat diet to be common risk factor for T2DM and AD (Edwards et al., 2011; Valls-Pedret and Ros, 2013; Willette et al., 2015) . Based on this work, rodents models with various dietinduced AD-like alterations have been established to examine the pathogenesis of AD in T2DM (Arnold et al., 2014; Luo et al., 1998; McNeilly et al., 2011; Stranahan et al., 2008) . Using these models, several studies have demonstrated that brain insulin resistance is likely to be the main cause of AD-like alterations (Haan, 2006; Jayaraman and Pike, 2014; Kim and Feldman, 2012; Ma et al., 2015) . Insulin signalling is important for various neuronal functions (Belfiore et al., 2009) , and may be involved in the regulation of synaptic activities, cognitive processes (Zhao and Alkon, 2001) , and learning and memory (Kim and Feldman, 2015) . Furthermore, insulin stimulates Ab extracellular secretion to inhibit its intracellular accumulation (de la Monte, 2012; Gasparini et al., 2001; Pratico et al., 2001; Watson et al., 2003) and blocks GSK-3b via phosphorylation to inhibit neuronal tau phosphorylation (Balaraman et al., 2006; Clodfelder-Miller et al., 2005; Schubert et al., 2004; Takashima, 2006) . Therefore, AD may develop when insulin is unable to work in the brain due to brain insulin resistance (Kim and Feldman, 2012 ).
An adequate therapeutic treatment that targets AD in T2DM patients has not yet been established. Although metformin, which is a popular treatment for T2DM, has been applied to AD, its effects remain controversial (Gupta et al., 2011; McNeilly et al., 2012; Moore et al., 2013; Picone et al., 2015) . Meanwhile, we believe that agmatine could be a therapeutic option for treating AD in individuals with T2DM. Altered arginine metabolism is associated with diabetes (Lee et al., 2011) as well as the deterioration of memory functions, similar to those found in AD patients (Liu et al., 2014) . Arginine is metabolized into several bioactive molecules, including agmatine. Agmatine, an endogenous aminoguanidine compound made from arginine by arginine decarboxylase, has had positive effects in animal models of several diseases, such as diabetes, stroke, spinal cord injury, and cognitive decline (Ahn et al., 2014; Cui et al., 2012; Park et al., 2013; Song et al., 2014; Su et al., 2009) . For example, agmatine has exhibited anti-diabetic effects in type 1 and type 2 diabetic animals Hwang et al., 2005; Ko et al., 2008; Su et al., 2009) . Several studies have demonstrated the pharmacological potential of agmatine in treating cognitive decline and memory impairment in various animal models (Arteni et al., 2002; Liu and Bergin, 2009; McKay et al., 2002; Moosavi et al., 2014; Rastegar et al., 2011; Zarifkar et al., 2010) . Recently, agmatine has been shown to improve memory function in type 1 diabetes-induced memory decline . Also, our previous report revealed that agmatine activates insulin signal transductions in the brain to prevent cognitive decline induced by an intracerebroventricular streptozotocin injection (Song et al., 2014) .
Although the effects of agmatine on diabetes and memory impairment have been independently reported, the possible therapeutic effect of agmatine on AD-like alterations in T2DM mice characterized by brain insulin resistance has not yet been investigated. The aim of the present study was to show that the regulation of insulin signalling by agmatine attenuates AD-like alterations in T2DM mice characterized by brain insulin resistance.
Materials and methods

Materials
Agmatine, streptozotocin, and glucose were purchased from Sigma Aldrich (St. Louis, MO, USA). Antibodies against IRS-1, p-IRS-1 (Tyr 632), p-tau (Ser 202, Tyr 205), TNF-a, and IL-1b were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies for detecting Akt, amyloid beta, and horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit, and anti-goat IgG antibodies were purchased from Abcam (Cambridge, UK). Beta-actin, FITC, or rhodamine-conjugated donkey anti-rabbit or anti-mouse antibodies and 4 0 ,6-diamidino-2-phenylindole (DAPI) were purchased from Millipore (Billerica, MA, USA). Other antibodies against p-Akt (Ser473), p-GSK-3b (Ser9), and GSK-3b were purchased from Cell Signalling Technology (Beverly, MA, USA). The polyvinylidene difluoride (PVDF) membrane for western blot assay was purchased from Millipore. The chemiluminescence reagents (ECL) for western blot assay were from Life Technologies (Carlsbad, CA, USA). The high-fat diet (60% kcal fat) was purchased from Research Diets (New Brunswick, NJ, USA) and normal diet was purchased from LabDiet (St. Louis, MO, USA). The portable glucometer (CareSensII Meter) was purchased from Pharmaco (NZ) Ltd. (Auckland, New Zealand). The serum insulin ELISA was purchased from ALPCO (Windham, NH, USA) and tissue insulin ELISA was purchased from Shibayagi (Gumma, Japan). The amyloid beta ELISA is purchased from Invitrogen (Carlsbad, CA, USA). All the other chemicals used in this experiment were purchased from Sigma Aldrich.
Establishment of the T2DM mice with AD-like alterations characterized by brain insulin resistance
Adult male ICR mice (7 weeks old, Central Lab Animal Inc., Seoul, Korea) were used in this study. The mice were raised in a standard laboratory animal facility under a 12 h light/dark cycle and had free access to food and water ad libitum. All procedures were conducted in accordance with the Yonsei University College of Medicine Animal Care and Use Committee and the National Institutes of Health guidelines for the Care and Use of Laboratory Animals. We modified previously established methods (Byrne et al., 2015; Jiang et al., 2012; Luo et al., 1998; Rahigude et al., 2012; Tahara et al., 2011) to develop a T2DM mouse model with AD-like alterations characterized by brain insulin resistance. After a week of acclimatization to the laboratory conditions, mice were randomly divided into two groups. Mice were administered either a normal chow diet (NC; 13.1% kcal fat) or a high-fat diet (HFD; 60% kcal fat) for 12 weeks (Table 1 ). The mice fed HFD were injected once at week 4 with a low dose of streptozotocin [STZ; 100 mg/kg/ip, dissolved in citrate buffer (pH 4.4)] to shorten the time taken for the animal model to be established by inducing partial insulin deficiency (Fig. 1) . Mice with fasting serum glucose level >200 mg/dl, body weight >55 g, and impaired glucose, insulin tolerance were classified as T2DM (Tabak et al., 2012) . T2DM mice were divided into two groups: HFD mice treated with saline and HFD mice treated with agmatine (HFD þ AGM; 100 mg/kg/ip, dissolved in saline). These groups were treated with agmatine daily for 2 weeks (Fig. 1) . Twelve mice were included in each group (a total of 36 mice were used).
Determination of body weight and serum glucose levels
Body weights (BW) and fasting serum glucose levels (Piletz et al., 2013) of all animals were monitored weekly. To measure fasting glucose levels, mice were fasted for 4 h before the test. Blood glucose concentrations from blood samples taken from the tip of the tail were measured using a glucometer.
Intraperitoneal glucose tolerance test (IPGTT)
Glucose tolerance test is a widely used clinical test to diagnose glucose intolerance and T2DM (American Diabetes, 2007; Muniyappa et al., 2008) . Food was removed a night before the test. The mice were injected with glucose (2 g/kg/ip, dissolved in saline). Blood glucose levels from blood samples taken from the tip of the tail were measured using a glucometer at 0, 30, 60, and 120 min after the bolus. The area under the concentration versus time curve (AUC glucose 0e120 min, mg/dl * minutes) was calculated.
Intraperitoneal insulin tolerance test (IPITT)
Mice were fasted for 4 h before the test. The mice were injected with insulin (0.75 U/kg/ip, dissolved in saline). Blood glucose levels from blood samples taken from the tip of the tail were measured using a glucometer at 0, 15, 30, 60, and 120 min after the bolus. The The Morris water maze test was conducted for evaluating spatial learning and reference memory depending on hippocampus using a previously established protocol (Morris et al., 1982) with some modifications. Our test consisted of 4 days of training and a test session on day 6. Mice were transferred from their home cage to the behaviour room to adapt to the new environment for at least 30 min before each session. The apparatus consisted of a circular water pool (100 cm in diameter, 35 cm in height) that was filled with opaque water to a depth of 15.5 cm. A platform (5.5 cm in diameter, 14.5 cm in height) was placed at a fixed location. Four different figures were attached on the wall as visual cues. Each mouse received four trainings per day for 4 consecutive days. During each training session, the escape latency from the water to the platform was measured. All mice were allowed to find the platform for a maximum of 90 s. On day 5, a test session was conducted in which the mice were allowed to swim freely in the pool without the platform for 90 s. The time spent in the quadrant where the platform was previously located was measured.
Nest building test
The nest building test was conducted after MWM for evaluating hippocampal function. The mice were moved into individual cages with a cotton pad (50 Â 50 mm, 5 g). After 24 h, each nest was recorded and scored on a scale of 1e5 by five researchers according to the established criteria (Deacon, 2006) . These criteria include scores for the shape of the nest and the amount of material used.
Tissue sample preparation
After the behaviour tests, the mice were transcardially perfused with saline and their brains were removed. Two hemispheres from each brain were randomly selected for either western blot or immunohistochemistry. Hemispheres for immunohistochemistry were incubated in 4% paraformaldehyde (PFA) for 24 h at 4 C and then transferred to a 30% sucrose solution for 1 week. These hemispheres were embedded in medium (Tissue-Tek
Compound, Sakura Finetek USA, Inc., Torrance, CA, USA), cut into 20 mm slices on a cryostat, and stored at À20 C until immunohistochemistry was performed. The hemispheres for western blot assay were placed in saline and carefully dissected. The hippocampus and cortex regions were immediately frozen in liquid nitrogen and stored until western blot assay.
Immunofluorescence
The sections were mounted on tissue slides and then permeabilized with 0.025% Triton X-100. The sections were blocked with 10% donkey serum at room temperature for 1 h. The sections were immunostained with primary antibodies against p-tau ( 
Western blot assay
The hippocampus and cortex were treated with lysis buffer containing inhibitor cocktails and isolated protein from the homogenizer (Dremel, Racine, WI, USA). The protein concentration was determined using the BCA method. A total of 50 mg of protein was separated on 6% or 10% SDS-PAGE gels and electrotransferred onto a PVDF membrane. After blocking the membrane with 5% bovine serum albumin, the membranes were reacted with primary antibodies that specifically detect IRS-1 (1:1000), p-IRS-1 (Tyr 632, 1:1000), Akt (1:1000), p-Akt (Ser473, 1:1000), p-GSK-3b (Ser9, 1:1000), GSK-3b (1:1000), p-tau (Ser 202, Tyr 205, 1:1000), Ab
(1:1000), TNF-a (1:1000), IL-1b (1:1000) and b-actin (1:2500) at 4 C overnight. After washing with TBS (0.5% with Tween 20), the membranes were reacted with HRP-conjugated anti-mouse, antirabbit, or anti-goat IgG antibodies (1:3000) at room temperature for 1 h. After washing with TBS (0.5% with Tween 20), signals were observed using enhanced ECL reagents. The images were captured by the chemi-luminescent image analyzer (LAS 4000, Fujifilm, Tokyo, Japan).
Serum and tissue insulin ELISA assay
Serum insulin was measured with an insulin ELISA kit (ALPCO, Windham, NH, USA), and tissue insulin was measured with an insulin ELISA kit (Shibayagi, Gumma, Japan). We loaded 10 mL of each of the standard, control, and experimental samples into Timeline for the in vivo study. Mice were randomly assigned into two groups and then fed either a normal diet (NC) or a high-fat diet (HFD) for 12 weeks. HFD-fed mice were injected once at week 4 with streptozotocin (STZ; 100 mg/kg/ip). Mice with a fasting serum glucose level >200 mg/dl, body weight >55 g, and impaired glucose tolerance were selected and then randomly divided into two groups: HFD mice treated with saline and HFD mice treated with agmatine (HFD þ AGM; 100 mg/kg/ip) for 2 weeks. Behaviour tests were conducted prior to sacrifice. appropriate wells. Then, we added 75 mL of enzyme conjugate (mouse monoclonal anti-insulin conjugated to biotin) into each well and incubated for 2 h at room temperature, shaking at 800 rpm on a microplate shaker. Microplates were washed six times with 350 mL of wash buffer. Then, we added 100 mL of substrate solution (tetramethylbenzidine) to each well and incubated the samples for 15 min at room temperature, shaking at 800 rpm on a microplate shaker. The enzymatic reaction was stopped by adding 100 mL of stop solution to each well, and absorbance was measured at 450 nm using a microplate reader.
Amyloid beta ELISA assay
Tissue amyloid beta was measured with an amyloid beta ELISA kit. Samples were prepared using 5 M guanidine HCl/50 mM Tris HCl solution with protease inhibitor cocktail containing AEBSF.
Briefly, we loaded 100 mL of each of the standard, control, and experimental samples into appropriate wells and incubated the specimens for 2 h at room temperature. We then washed the microplate four times with 400 mL of wash buffer. Then, 100 mL of detection antibody was added into each well and incubated for 1 h at room temperature. The microplate was then washed four times with 400 mL of wash buffer. Then, we added 100 mL of HRP antirabbit antibody to each well and incubated the specimens for 30 min at room temperature. We then washed the microplate again four times with 400 mL of wash buffer. Then, we added 100 mL of stabilized chromogen to each well and incubated the specimens for 30 min at room temperature. The enzymatic reaction was stopped by adding 100 mL of stop solution to each well, and absorbance was determined at 450 nm using a microplate reader.
Serum analysis
Serum levels of total cholesterol and triglyceride were measured by chemistry analyzer, Fuji dri-chem 4000i (Fuji photo film, Tokyo, Japan) and Fuji dri-chem slides. Fuji dri-chem slide contains suitable enzymes for separating a factor that we wanted to measure from serum. 10 mL of sample was dropped onto each slide to induce enzymatic reaction, and then slides were read using Fuji dri-chem 4000i.
Statistical analysis
All experiments were repeated at least three times, and the data are expressed as the mean ± standard deviation (SD). Statistical analysis was performed by a one-way analysis of variance (ANOVA), followed by Tukey's post hoc analysis. Statistical significance was defined as * p 0.05 and **p 0.01 vs. NC.
Results
3.1. Agmatine treatment restores insulin sensitivity, reducing peripheral glucose intolerance, insulin intolerance, and serum triglyceride levels and increasing serum insulin levels in HFD-fed mice To induce brain insulin resistance, 8-week-old ICR mice were fed a 60% high-fat diet for 12 weeks. As shown in Fig. 2 , the high-fat diet induced significant weight gain (NC vs. HFD, average weight: week 0, 39.93 ± 0.86 mg vs. 40.68 ± 1.83 mg; week 12, 48.68 ± 4.22 mg vs. 66.69 ± 6.8 mg, Fig. 2A ) and increased fasting serum glucose levels (NC: 155 ± 13.49 mg/dl vs. HFD: 522 ± 31.6 mg/dl at 14 weeks, Fig. 2B ). Most importantly, glucose tolerance and insulin tolerance were significantly impaired in the HFD group, compared with the NC group (difference of 162 095 mg/dl*min in the AUC of the IPGTT between the HFD and NC mice, Fig. 2C and D ; difference of 27 017.5 mg/dl*min in the AUC of the IPITT between the HFD and NC mice, Fig. 2E and F) . One low-dose injection of STZ was used to mimic pancreas failure in the pathogenesis of T2DM; STZ evoked no significant damage to the pancreas (Supplementary Fig. 1 ). Despite normal pancreatic function, characteristics of T2DM and insulin resistance, including increases in body weight, fasting serum glucose level, glucose intolerance and insulin intolerance, were induced by 12 weeks of a high-fat diet.
After 2 weeks of agmatine treatment, glucose and insulin intolerance were significantly recovered (p > 0.01, HFD vs. HFD þ AGM, Fig. 3FeI ). While no significant difference in body weight or 4-hour fasting serum glucose levels were found (Fig. 3A  and B) , overnight fasting serum glucose levels were significantly lower (Fig. 3C) .
Mouse serum insulin ELISA assay revealed that the high fat-diet increased serum insulin concentrations, compared with NC (Fig. 3D) . Serum analysis showed that HFD mice had lower total cholesterol and higher triglyceride than NC, although agmatine treatment lowered triglyceride levels and increased total cholesterol level (Fig. 3E) . Based on the results of IPGTT, IPITT, overnight fasting serum glucose level, insulin ELISA, and serum analysis, we can conclude that agmatine treatment restores insulin sensitivity in high-fat diet fed mice.
Agmatine treatment rescues reduced insulin signalling in the brain of HFD-fed mice
To evaluate the effect of agmatine on brain insulin resistance induced by the high-fat diet, the amount of insulin in the brain was measured by ELISA, and the expression levels of p-IRS-1 and p-Akt in both the cortex and the hippocampus were measured by western blot assay. As seen in Fig. 4 , the amount of insulin and the protein expression levels of p-IRS-1 and p-Akt were significantly reduced in both the cortex and the hippocampus of the HFD mice (insulin, p > 0.05 vs. NC; p-IRS-1, p > 0.05 vs. NC; p-Akt, p > 0.05 vs. NC), compared with NC mice. However, HFD þ AGM mice exhibited significantly higher levels of insulin, p-IRS-1, and p-Akt (insulin, p > 0.05 vs. HFD; p-IRS-1,p > 0.05 vs. HFD; p-Akt, p > 0.05 vs. HFD) in the cortex and the hippocampus of the mice. The amount of insulin and phosphorylated molecules in HFD þ AGM mice was similar to those in NC mice in both the cortex (p-IRS-1, 93%, p-Akt, 166% as a percentage of NC) and the hippocampus (p-IRS-1, 94%; pAkt, 127% as percentage of NC).
3.3. 3Agmatine treatment restores the phosphorylation of glycogen synthase kinase-3b in both the cortex and hippocampus of HFD-fed mice Among the molecules downstream from insulin, glycogen synthase kinase-3b (GSK-3b) is well known to phosphorylate tau leading to production of neurofibrillary tangles and Alzheimer's disease. Normally, insulin downstream signals inhibit GSK-3b by phosphorylation at serine 9 so that GSK-3b cannot phosphorylate tau. Western blot assays and immunofluorescence were conducted to confirm the ability of agmatine to restore the phosphorylation of GSK-3b in mice with brain insulin resistance. As seen in Fig. 5A and B, the western blot assay revealed that the protein expression of p-GSK-3b was significantly decreased in both the cortex and the hippocampus in HFD mice, compared with NC mice (p > 0.05 vs. NC). However, the expression of p-GSK-3b was significantly higher in both the cortex and the hippocampus in HFD þ AGM mice (p > 0.05 vs. HFD). The level of p-GSK-3b in HFD þ AGM mice was similar to p-GSK-3b in NC mice in both the cortex (91% as a percentage of NC mice) and the hippocampus (95% as a percentage of 
NC mice).
Immunofluorescence revealed that the expression of p-GSK-3b was significantly reduced in the cortex and the hippocampus of HFD mice, except in CA3 of the hippocampus (Fig. 5CeF ) (frontal cortex, p < 0.01 vs. NC; lateral cortex, p < 0.01 vs. NC; DG, p < 0.01 vs. NC; CA1, p < 0.01 vs. NC; CA2, p < 0.01 vs. NC). However, repeated agmatine administration significantly restored the expression of p-GSK-3b in the cortex and the hippocampus (frontal cortex, p < 0.01 vs. HFD; lateral cortex, p < 0.01 vs. HFD; CA1, p > 0.05 vs. HFD; CA2, p < 0.01 vs. HFD; CA3, p < 0.01 vs. HFD), except in the dentate gyrus. These results are consistent with the western blot assay results ( Fig. 5A and B) .
Agmatine injection attenuates the phosphorylation of tau in both the cortex and hippocampus of high-fat diet-fed mice
Western blot assay and immunohistochemistry were conducted to examine whether the ability of agmatine to increase the phosphorylation of GSK-3b leads to a reduction of phosphorylated tau in diabetic mice with brain insulin resistance. The western blot assay revealed that the expression of p-tau was increased in HFD mice, compared with NC mice, in both the cortex and the hippocampus (cortex, p < 0.01 vs. NC; hippocampus, p < 0.01 vs. NC). However, the expression of p-tau was significantly reduced in HFD þ AGM mice, compared with HFD mice, in both the cortex and the hippocampus (cortex, p < 0.01 vs. HFD; hippocampus, p < 0.01 vs. HFD) (Fig. 6A and B) .
Immunofluorescence revealed that the number of positive p-tau spots was significantly increased in HFD mice, compared with NC mice (frontal cortex, p < 0.01 vs. NC; lateral cortex, p < 0.05 vs. NC). Repeated treatment with agmatine significantly lowered the expression of p-tau in the cortex (frontal cortex, p < 0.01 vs. HFD; lateral cortex, p < 0.05 vs. HFD) (Fig. 6C and D) . Similarly, the number of positive spots of p-tau were significantly higher in the DG and CA3 regions of the hippocampus in HFD mice, compared with NC mice (DG, p < 0.01 vs. NC; CA3, p<0.01 vs. NC) (Fig. 6D, F) . However, the repeated agmatine administration significantly lowered the expression of p-tau in the hippocampus (DG, p < 0.01 vs. HFD; CA1, p < 0.05 vs. HFD; CA2, p < 0.01 vs. HFD; CA3, p < 0.01 vs. HFD) (Fig. 6E and F) .
Agmatine treatment reduces the accumulation of amyloid beta in both the cortex and the hippocampus of high-fat diet-fed mice
Western blot assay, immunohistochemistry, and tissue ELISA were conducted to investigate whether the agmatine-mediated activation of blunted insulin signals in the brain reduces the accumulation of Ab. As shown in Fig. 7A B, G, the western blot assay and tissue ELISA revealed that the amount of Ab was increased in HFD mice, compared with NC mice (hippocampus, p < 0.01 vs. NC; cortex, p < 0.01 vs. NC). However, the expression of Ab was significantly decreased in HFD þ AGM mice, compared with HFD mice (hippocampus, p < 0.01 vs. HFD; cortex, p < 0.01 vs. HFD). All species of amyloid beta protein bands are presented in Supplementary Fig. 2 .
Immunofluorescence revealed that the expression of Ab was significantly higher in HFD mice, compared with NC mice (frontal cortex, p < 0.01 vs. NC; lateral cortex, p < 0.05 vs. NC). Repeated treatment with agmatine significantly lowered the expression of Ab in the cortex (frontal cortex, p < 0.01 vs. HFD; lateral cortex, p < 0.05 vs. HFD) (Fig. 6C and D) . The number of positive spots of Ab were significantly increased in the hippocampus of HFD mice, except in the DG (CA1, p < 0.01 vs. NC; CA2, p < 0.01 vs. NC; CA3, p < 0.01 vs. NC). Repeated agmatine administration significantly lowered the expression of Ab in the hippocampus, except in the DG (CA1, p < 0.01 vs. HFD; CA2, p < 0.01 vs. HFD; CA3, p < 0.01 vs. HFD) (Fig. 6E and F) .
Agmatine administration improves learning and memory function in high-fat diet-fed mice
Behaviour tests were conducted to determine whether the reduction in the expression levels of Ab and p-tau by agmatine leads to an improvement in learning and memory function. Morris water maze test is conducted to evaluate spatial learning and preference memory depending on hippocampus. In addition, MWM has been shown that there is involvement of the entorhinal and perihinal cortices, as well as involvement of the prefrontal cortex, the cingulated cortex, the neostriatum, and perhaps even the cerebellum in a more limited way. In the MWM, a significant increase in escape latency on the last day of training was observed in HFD mice, compared with NC mice (p < 0.05 vs. NC) (Fig. 8A) . HFD mice spent significantly less time in the quadrant where the platform was located during the test, compared with NC mice (p < 0.01 vs. NC) (Fig. 8B) . However, the amount of time spent in the platform quadrant was significantly longer in HFD þ AGM mice, compared with HFD mice (p < 0.01 vs. HFD) (Fig. 8B) .
Nest building test is conducted to evaluate hippocampal function, as some publications report that lesions of the medial preoptic area, septum, or hippocampus impair nesting behaviour. HFD mice received lower scores on the nest building test, compared with NC mice (p < 0.01 vs. NC). However, HFD þ AGM mice received significantly higher scores than HFD mice (p < 0.01 vs. HFD) (Fig. 8C) .
Collectively, agmatine improved hippocampal functions, such as learning and memory, induced by high-fat diet through the activation of insulin signalling in type 2 diabetic mice with AD-like alterations characterized by brain insulin resistance (Fig. 9) .
Discussion
In the present study, we demonstrated the effect of agmatine on AD-like alterations in patients with T2DM characterized by brain insulin resistance. Agmatine administration improved insulin actions and rescued the reduced expressions of p-IRS-1, p-Akt, and p-GSK-3b in the brain of high-fat diet-fed mice. Agmatine treatment reduced the amounts of Ab and p-tau accumulation in the brain, and improved impairments in learning and memory functions in high-fat diet-fed mice.
There are two types of therapeutics of determine, insulin sensitizers and drugs effective for insulin production. The latter ones increase amounts of insulin, although agmatine did not increase serum insulin levels (Fig. 3D) . Insulin sensitizer is effective for regulating pre-prandial serum glucose levels, not post-prandial serum glucose levels, and agmatine showed coherent action as shown in Fig. 3B and C. The reductions of serum insulin level, decreases in overnight fasting serum glucose level, and improvement of insulin tolerance and glucose tolerance in the agmatine treated group indicated that agmatine improves insulin sensitivity. According to some research, agmatine improves insulin sensitivity by activation of I2-imidazolin receptors in adrenal gland in diabetic animal models Hwang et al., 2005; Ko et al., 2008; Su et al., 2009) . Accordingly, we suggest that agmatine exerts anti-diabetic effects by improving insulin sensitivity. In addition that, high-fat diet lowered total cholesterol while triglyceride level was increased by high-fat diet (Fig. 3E) , suggesting triglyceride takes up most cholesterol in HFD mice. However, agmatine treated mice showed high level of total cholesterol and low level of triglyceride, meaning most of cholesterol could be LDL, not triglyceride. According to a paper, which has similar experimental design with ours, 12 weeks of 60% high-fat diet caused increase in triglyceride and LDL but decrease in HDL (Sharawy et al., 2016) . However, 3 weeks of agmatine treatment reduced triglyceride and LDL. In addition to total cholesterol and triglyceride measurement, we could say animals used in present study would show similar changes in LDL and HDL with that reference paper.
Brain insulin resistance was induced by 12 weeks of a high-fat diet, and was characterized by blunted insulin signal transductions as observed in the expression levels of p-IRS-1, p-Akt, and p-GSK-3b (Figs. 4 and 5 ) and decreased insulin levels (Fig. 4B ). Brain insulin resistance leads to both Ab plaque formation and tau hyperphosphorylation (Kim and Feldman, 2012) . Insulin inhibits the accumulation of Ab via the stimulation of Ab extracellular secretion (de la Monte, 2012; Gasparini et al., 2001; Watson et al., 2003) . Insulin resistance induces oxidative stress and neuroinflammation, which promotes Ab accumulation and toxicity (Pratico et al., 2001) . Although GSK-3b phosphorylates tau, the phosphorylation of GSK-3b at serine 9 by insulin inhibits its action on tau. Therefore, a reduced insulin signal increases GSK-3b activity, leading to tau phosphorylation (Balaraman et al., 2006; Clodfelder-Miller et al., 2005; Takashima, 2006) . In our study, the expression levels of Ab and p-tau were increased, and neuroinflammation developed in the brain of mice in the high-fat diet group (Figs. 6 and 7, Supplementary Fig. 3 ), which is consistent with previous findings.
According to prior reports, T2DM affects cognitive processes, such as memory and executive function (Sims-Robinson et al., 2010) . The hippocampus, which has the highest concentration of insulin receptors in the brain (Freude et al., 2009; Gammeltoft et al., 1985) , is vulnerable to insulin resistance. A high-fat diet increases hippocampal oxidative stress, which reduces NF-E2-related factor 2 (Nrf2) signalling (Morrison et al., 2010) , causes mitochondrial homeostasis deficiency (Petrov et al., 2015) , and impairs hippocampus-dependent memory function (McNeilly et al., 2011) . The MWM test is used to evaluate spatial memory depends primarily on the hippocampus. In our study, high-fat diet-fed mice displayed spatial memory impairment (Fig. 8 A,B) , which is consistent with previous findings.
The deterioration of activities of daily living is an early sign of AD (Filali et al., 2012; Wesson and Wilson, 2011) . In mice, injuries to the cortex and hippocampus can affect nesting behaviour (Deacon et al., 2002 (Deacon et al., , 2003 . Nest building ability is negatively correlated with Ab accumulation in the brain (Wesson and Wilson, 2011) . In our study, nest building function was impaired in HFD mice (Fig. 9C) , which suggests that brain insulin resistance induced impairment of brain function.
The expression levels of p-IRS-1, p-Akt, and p-GSK-3b were increased in the brain of the HFD-AGM mice up to similar levels as those observed in NC mice. These results indicate that the insulin signals were being transmitted and phosphorylating IRS-1, Akt, and GSK-3b in the brain of the type 2 diabetic mice with AD-like alterations characterized by brain insulin resistance. Following the activation of the blunted insulin signals in the brain, treatment with agmatine significantly reduced Ab and p-tau and improved memory function, which indicates that agmatine treatment reversed the AD-like alterations in high-fat diet-fed mice.
The increased expression of p-IRS-1 in the brain by agmatine treatment is a novel finding of this study. It has been reported that agmatine prevents memory deficits via the activation of ERK, Akt, and GSK-3b (Moosavi et al., 2012 (Moosavi et al., , 2014 . Our result adds to this previous work by showing that agmatine activates not only Akt and GSK-3b but also their upstream signal regulator IRS-1.
Among the molecules activated by insulin receptor kinase, members of the IRS family recruit downstream signalling molecules, including phosphatidylinositol 3-dinase (PI3K) (Saltiel and Kahn, 2001) . The phosphorylation of the tyrosine residues of IRS-1 promotes the metabolic functions of insulin, whereas the dephosphorylation of tyrosine and the phosphorylation of the serine/threonine residues dissociate IRS-1 from the insulin receptor and reduce insulin signalling (Kapogiannis et al., 2015) . Many inducers of insulin resistance activate IRS serine kinases. Among these inducers, there are two kinds of serine kinases. One type of serine kinase is related to insulin signalling and includes kinases, such as the mammalian target of rapamycin (mTOR)/S6K1 and mitogen-activated protein kinase (MAPK). The other type of serine kinase is activated along unrelated pathways, and includes kinases, such as GSK-3b and c-Jun NH2-terminal kinase (JNK) (Ozcan et al., 2004) . Physical exercise or pharmacological chemicals, such as thiazolidinedione (TZD) and metformin, improve insulin action via the inhibition of iNOS and mTOR/S6K1 signalling (Marette, 2008 ; Fig. 9 . The effect of agmatine on brain insulin resistance. Type 2 diabetes induces Alzheimer's disease-like alterations through blunted insulin signalling in the brain as it leads to the accumulation of Ab, the phosphorylation of tau, and cognitive decline. However, agmatine activates the insulin signals in the diabetic mice with AD-like alterations characterized by brain insulin resistance to restore normal brain function. Agmatine reverses the Alzheimer's disease-like alterations induced by type 2 diabetes. Pilon et al., 2004) . Agmatine reduces the phosphorylation of JNK (Hong et al., 2007; and iNOS (Mun et al., 2010; Wang et al., 2010) under severe conditions, such as hypoxia, stroke, and traumatic injury. Therefore, agmatine might reduce the phosphorylation of iNOS and JNK in the brain of the T2DM mice with AD-like alterations characterized by brain insulin resistance to activate IRS-1.
The rescue of the blunted insulin signal in the hippocampus and the cortex by agmatine revived hippocampus-dependent memory function and cortex-and hippocampus-dependent nest building ability. HFD þ AGM mice performed better on the MWM test than NC mice. Another reason why agmatine improves hippocampusdependent spatial learning is that agmatine could be able to function as a neurotransmitter. The amount of agmatine is reduced in the superior frontal gyrus, cerebellum, and hippocampus of AD patients and AD rats (Liu et al., 2008a (Liu et al., , 2014 . Spatial learning enhances agmatine level in the hippocampus and the cortex (Leitch et al., 2011; Liu et al., 2008b) . It is, therefore, possible that agmatine functioned as a neurotransmitter in this study to improve learning and memory function in the hippocampus.
Further studies are needed to confirm the direct relationship between brain insulin resistance and agmatine. Since agmatine was injected intraperitoneally, it is unclear whether AD-like alterations were rescued by agmatine directly or by recovering T2DM. An agmatine treatment in neuronal insulin resistance in vitro model could be helpful for clarifying the direct functions of agmatine on brain insulin resistance.
In conclusion, this study suggests that agmatine has the potential to rescue AD-like alterations in T2DM mice characterized by brain insulin resistance via the regulation of IRS-1, Akt, and GSK-3b. Agmatine attenuates AD-like alterations caused by brain insulin resistance by reducing Ab and p-tau, and improves impaired hippocampal functions, such as learning and memory, via the activation of blunted insulin signal transduction in the brain (Fig. 9) .
